All News

Found 2,730 articles

• CRISPR And Casebia Therapeutics Announce Exclusive Development And Option Agreement With StrideBio

  4/17/2017

• Patent Fight Continues as CRISPR, Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision

  4/13/2017

• Massachusetts Startup Frequency Therapeutics Nabs $32 Million

  4/12/2017

• Intellia Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent

  4/11/2017

• Charles River Announces Launch Of Triple-Immunodeficient Mouse Model For Oncology Research

  4/3/2017

• Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers

  3/31/2017

• Cellecta, Inc. Launches Driver-Map Human Genome-Wide Gene Expression Profiling Kit For 19,000 Human Genes

  3/29/2017

• ERS Genomics Release: European Patent Office To Grant Broad Claims On Patent Covering CRISPR-Cas9 Gene Editing Technology

  3/28/2017

• Turns Out Editas Medicine's R&D Deal With Allergan Could be Worth $1 Billion

  3/24/2017

• Intellia’s CEO Has Cambridge-Based Company Moving Forward on Positive in vivo Data

  3/22/2017

• Synthego Announces Modified Synthetic sgRNA -- Critical For Editing Primary And Stem Cells, And Other Challenging Cell Types

  3/22/2017

• St. Jude Children's Research Hospital Release: Caution Needed For Drugs In Development For Most Common Malignant Pediatric Brain Tumor

  3/22/2017

• Proteintech Announces Winners Of AACR 2017 Travel Grants

  3/16/2017

• Cellecta, Inc. Announces Upcoming Presentations At AACR 2017 Annual Meeting

  3/15/2017

• Allergan Pays $90 Million to Get Into CRISPR, Will Have the Option to License Five Programs From Editas Medicine

  3/14/2017

• CRISPR And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc.

  3/14/2017

• Lycera Announces The Appointment Of Pablo J. Cagnoni, M.D., To The Board Of Directors

  3/13/2017

• Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine’s HQ

  3/8/2017

• Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa

  3/8/2017

• Horizon Discovery Ltd. Enters Into R&D And Licensing Partnership With Amplycell S.A. For Bioproduction Cell Line Optimization

  3/8/2017